Agios Pharmaceuticals

AGIO Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$35.20

+2.95% today

52W: $22.24 – $46.00

52W Low: $22.24 Position: 54.5% 52W High: $46.00

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

38.17x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$2.1B

Market Capitalization

Revenue Growth

86.1%

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-30.2%

Return on Equity

Beta

0.79

Market sensitivity

Short Interest

10.64%

% of float sold short

Avg. Volume

929,068

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

8 analysts

Avg. Price Target

$43.75

+24.29% upside

Target Range

$28.00 – $65.00

About the Company

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenyla

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 539 Exchange: NMS